Quickly Spot Consensus Among the World's Best Equity Analysts
| Name | Upside % |
Analysts bullish % |
|
|---|---|---|---|
|
102%
upside
3 price targets
|
0
%
|
|
|
|
102%
upside
8 price targets
|
0
%
|
|
|
|
101%
upside
4 price targets
|
0
%
|
|
|
104
Enanta Pharmaceuticals
ENTA
$312M
|
100%
upside
3 price targets
|
0
%
|
|
|
99%
upside
3 price targets
|
0
%
|
|
|
|
99%
upside
3 price targets
|
0
%
|
|
|
|
97%
upside
8 price targets
|
0
%
|
|
|
|
94%
upside
3 price targets
|
0
%
|
|
|
|
93%
upside
3 price targets
|
0
%
|
|
|
|
92%
upside
6 price targets
|
0
%
|
|
|
111
Nurix Therapeutics
NRIX
$1.28B
|
91%
upside
7 price targets
|
0
%
|
|
|
91%
upside
5 price targets
|
0
%
|
|
|
|
90%
upside
9 price targets
|
0
%
|
|
|
|
89%
upside
5 price targets
|
0
%
|
|
|
|
87%
upside
10 price targets
|
0
%
|
|
|
|
87%
upside
3 price targets
|
0
%
|
|
|
|
86%
upside
5 price targets
|
0
%
|
|
|
|
86%
upside
8 price targets
|
0
%
|
|
|
|
86%
upside
4 price targets
|
0
%
|
|
|
|
85%
upside
8 price targets
|
0
%
|
|
|
|
84%
upside
8 price targets
|
0
%
|
|
|
|
84%
upside
3 price targets
|
0
%
|
|
|
|
83%
upside
7 price targets
|
0
%
|
|
|
|
83%
upside
4 price targets
|
0
%
|
|
|
|
83%
upside
3 price targets
|
0
%
|
|